GINAI
    News Wire
    Markets

    Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4

    Yahoo FinanceJanuary 12, 2026 at 2:05 PMBullish1 min read

    Vertex Pharmaceuticals (VRTX) saw a strong performance in Q4, primarily driven by robust sales of its cystic fibrosis (CF) drugs. The company's innovative treatments in the CF space continue to demonstrate significant market penetration, contributing to its positive financial results for the quarter.

    Related Topics

    VRTXVertex PharmaceuticalsCystic FibrosisQ4 EarningsDrug Sales

    Related Articles

    Inflation isn’t going to slow anytime soon, even if the Iran cease-fire holds. Here’s why.

    neutral
    MarketWatch
    about 1 hour ago

    Short Sellers Squeezed Hard as Avis Budget Shares Rocket 150%

    neutral
    Bloomberg
    about 1 hour ago

    Flight Training Firm CAE Cuts Jobs Ahead of May Business Update

    neutral
    Bloomberg
    about 1 hour ago

    3 Reasons SABR is Risky and 1 Stock to Buy Instead

    neutral
    Yahoo Finance
    about 1 hour ago

    You May Also Like

    Inflation isn’t going to slow anytime soon, even if the Iran cease-fire holds. Here’s why.

    MarketWatch•about 1 hour ago

    Short Sellers Squeezed Hard as Avis Budget Shares Rocket 150%

    Bloomberg•about 1 hour ago

    Flight Training Firm CAE Cuts Jobs Ahead of May Business Update

    Bloomberg•about 1 hour ago

    3 Reasons SABR is Risky and 1 Stock to Buy Instead

    Yahoo Finance•about 1 hour ago

    Paraguay Names Lovera as Finance Chief to Bolster ‘Agile State’

    Bloomberg•about 1 hour ago

    Oil Prices in the North Sea Soar, Showing Supply Is Tight Despite Iran Ceasefire

    Bloomberg•about 2 hours ago